A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

BACKGROUND: In men with a rising PSA following radical prostatectomy, salvage radiation therapy (SRT) offers a second chance for cure. Hormonal therapy can be combined with SRT in order to increase prostate tumor control, albeit with associated higher rates of treatment side effects. This trial stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapoor, Roche, Deek, Matthew P., McIntyre, Riley, Raman, Natasha, Kummerlowe, Megan, Chen, Iyah, Gaver, Matt, Wang, Hao, Denmeade, Sam, Lotan, Tamara, Paller, Channing, Markowski, Mark, Carducci, Michael, Eisenberger, Mario, Beer, Tomasz M., Song, Daniel Y., DeWeese, Theodore L., Hearn, Jason W., Greco, Stephen, DeVille, Curtiland, Desai, Neil B., Heath, Elisabeth I., Liauw, Stanley, Spratt, Daniel E., Hung, Arthur Y., Antonarakis, Emmanuel S., Tran, Phuoc T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567492/
https://www.ncbi.nlm.nih.gov/pubmed/31196032
http://dx.doi.org/10.1186/s12885-019-5805-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567492/
https://www.ncbi.nlm.nih.gov/pubmed/31196032
http://dx.doi.org/10.1186/s12885-019-5805-z

Ejemplares similares